(2S)-2-Isopropylpyrrolidine | 41720-99-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2S)-2-Isopropylpyrrolidine
• 英文别名: (2S)-2-propan-2-ylpyrrolidine
• CAS: 41720-99-4
• 化学式: C₇H₁₅N
• mdl: MFCD01631842
• 分子量: 113.2
• InChiKey: UOADRGAJWNJVGC-ZETCQYMHSA-N

物化性质

• 沸点：
  140.2±8.0 °C(Predicted)
• 密度：
  0.827±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (2S)-2-Isopropylpyrrolidine 、 丙烯酰氯 、 N,N-二异丙基乙胺 以95%的产率得到
  参考文献：
  名称：

  JUNG, MICHAEL E.;VACCARO, WAYNE D.;BUSZEK, KEITH R., TETRAHEDRON LETT., 30,(1989) N5, C. 1893-1896

  摘要：

  DOI：
• 作为产物：
  描述：

  [(1S,2S,4S)-2-bicyclo[2.2.1]hept-5-enyl]-[(2S)-2-propan-2-ylpyrrolidin-1-yl]methanone 、 溶剂黄146 以65%的产率得到
  参考文献：
  名称：

  JUNG, MICHAEL E.;VACCARO, WAYNE D.;BUSZEK, KEITH R., TETRAHEDRON LETT., 30,(1989) N5, C. 1893-1896

  摘要：

  DOI：

文献信息

• N-(3,4-disubstituted phenyl) salicylamide derivatives
  申请人：TOKUYAMA Ryukou

  公开号：US20080227784A1

  公开（公告）日：2008-09-18

  A compound represented by the following formula (I) or a salt thereof: wherein R 1 , R 2 , R 3 and R 4 represent hydrogen atom, a halogen atom, cyano group, nitro group, a C 1-4 alkyl group, a halogenated C 1-4 alkyl group or a C 1-4 alkoxy group, R 5 represents a halogen atom, cyano group, a C 1-4 alkyl group, a halogenated C 1-4 alkyl group or a C 1-4 alkoxy group, R 6 represents a C 5-7 cycloalkyl group, a substituted C 5-7 cycloalkyl group, a 5 to 7-membered completely saturated heterocyclic group or a substituted 5 to 7-membered completely saturated heterocyclic group, X represents a single bond, oxygen atom, sulfur atom, NR 7 , —O—CH 2 — or —N(R 8 )—CH 2 —, R 7 represents hydrogen atom or a C 1-4 alkyl group, or R 7 may combine with a substituent of R 6 to represent a single bond, methylene group or ethylene group, R 8 represents hydrogen atom, a C 1-4 alkyl group or a C 7-12 aralkyl group, which is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of diseases caused by an activation of STAT6 and/or NF-κB.

  由以下式（I）表示的化合物或其盐：其中R1、R2、R3和R4代表氢原子、卤原子、氰基、硝基、C1-4烷基、卤代C1-4烷基或C1-4烷氧基，R5代表卤原子、氰基、C1-4烷基、卤代C1-4烷基或C1-4烷氧基，R6代表C5-7环烷基、取代的C5-7环烷基、5至7-成员完全饱和杂环基或取代的5至7-成员完全饱和杂环基，X代表单键、氧原子、硫原子、NR7、—O—CH2—或—N(R8)—CH2—，R7代表氢原子或C1-4烷基，或R7可以与R6的取代基结合以表示单键、亚甲基基团或乙烯基团，R8代表氢原子、C1-4烷基或C7-12芳基烷基，可用作药物的活性成分，用于预防和/或治疗由STAT6和/或NF-κB激活引起的疾病。
• Quinoline derivatives
  申请人：——

  公开号：US20020198194A1

  公开（公告）日：2002-12-26

  Quinoline derivatives are useful as neuropeptide Y (NPY) receptor ligands and are particularly effective as neuropeptide Y (NPY) antagonists. These compounds are useful in pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders, or obesity.

  喹啉衍生物在神经肽Y（NPY）受体配体中很有用，特别是作为神经肽Y（NPY）拮抗剂非常有效。这些化合物在制药制剂中很有用，用于治疗或预防关节炎、心血管疾病、糖尿病、肾衰竭、进食障碍或肥胖症。
• BENZIMIDAZOLE DERIVATIVES AND USE THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20150133500A1

  公开（公告）日：2015-05-14

  The invention provides compounds that are useful as sodium channel blockers. In one aspect, the invention provides compounds of Formula I: and pharmaceutically acceptable salts, solvates, hydrates, or diastereomers thereof, wherein W 1 , W 2 , W 3 , W 4 , U, G, m, R 1 , and R 2 are defined in the disclosure. In certain embodiments, the invention provides compounds of Formulae II to V as set forth supra. The invention also provides the use of compounds of any of the above discussed formulae to treat a disorder responsive to blockade of sodium channels. In one embodiment, Compounds of the Invention are useful for treating pain.

  该发明提供了作为钠通道阻滞剂有用的化合物。在一个方面，该发明提供了公式I的化合物：以及其药用可接受的盐、溶剂化合物、水合物或对映体，其中W1、W2、W3、W4、U、G、m、R1和R2在公开中有定义。在某些实施例中，该发明提供了如上所述的公式II至V的化合物。该发明还提供了利用上述讨论的任何公式的化合物来治疗对钠通道阻滞反应的疾病。在一个实施例中，该发明的化合物可用于治疗疼痛。
• [EN] PROCESSES FOR THE PREPARATION OF ARGINASE INHIBITORS AND THEIR SYNTHETIC INTERMEDIATES<br/>[FR] PROCÉDÉS DE PRÉPARATION D'INHIBITEURS D'ARGINASE ET LEURS INTERMÉDIAIRES SYNTHÉTIQUES
  申请人：INCYTE CORP

  公开号：WO2022016195A1

  公开（公告）日：2022-01-20

  Provided herein are processes and intermediates useful for the preparation of certain compounds, including a compound of formula 21 or formula 22 or a pharmaceutically acceptable salt of either.

  本文提供了用于制备某些化合物的过程和中间体，包括公式21或公式22的化合物，或者两者中任何一个的药用可接受盐。
• Antifungal agents
  申请人：Greenlee Mark L.

  公开号：US20100113439A1

  公开（公告）日：2010-05-06

  Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.

  本文披露了恩福马富金的新型衍生物，以及它们的药用盐、水合物和前药。还公开了包含这些化合物的组合物、制备这些化合物的方法以及将这些化合物用作抗真菌剂和/或(1,3)-β-D-葡聚糖合酶抑制剂的方法。这些公开的化合物、它们的药用盐、水合物和前药，以及包含这些化合物、盐、水合物和前药的组合物，可用于治疗和/或预防真菌感染及相关疾病和病况。